4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry

Forensic Toxicology

Volumn 34, Issue 1, 2016, Pages 61-75

  Ellefsen, Kayla N ^a,b   Wohlfarth, Ariane ^a   Swortwood, Madeleine J ^a   Diao, Xingxing ^a   Concheiro, Marta ^a,c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

Author keywords

4 Methoxy PVP; Human hepatocytes; Human liver microsomes; In silico prediction; Novel psychoactive substances; Synthetic cathinones

Indexed keywords

4 HYDROXY ALPHA PYRROLIDINOVALEROPHENONE; 4 METHOXY ALPHA PYRROLIDINOVALEROPHENONE; ILLICIT DRUG; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; HEPATIC CLEARANCE; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; MASS SPECTROMETRY; METABOLITE; MOLECULAR STABILITY; PREDICTION; PRIORITY JOURNAL;

EID: 84953348117     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0287-4     Document Type: Article

References (49)

1. EMCDDA (2015) New psychoactive substances in Europe—An update from the EU Early Warning System. Lisbon
2. United Nations Office on Drugs and Crime (2013) World Drug Report 2013. United Nations, Vienna
3. Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC 3rd, Garg U, Pietak BR (2012) Three fatal intoxications due to methylone. J Anal Toxicol 36:444–445
4. Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol 49:499–505
5. Tekulve K, Alexander A, Tormoehlen L (2014) Seizures associated with synthetic cathinone exposures in the pediatric population. Pediatr Neurol 51:67–70
6. Vardakou I, Pistos C, Spiliopoulou C (2011) Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201:191–195
7. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J (2011) Mephedrone: use, subjective effects and health risks. Addiction 106:1991–1996
8. Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, Ramsey J, Lee T, Holt DW, Dargan PI (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6:327–330
9. Thornton SL, Gerona RR, Tomaszewski CA (2012) Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 8:310–313
10. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K (2013) In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 5:430–438
11. Kriikku P, Wilhelm L, Schwarz O, Rintatalo J (2011) New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 210:195–200
12. Marinetti LJ, Antonides HM (2013) Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 37:135–146
13. Knoy JL, Peterson BL, Couper FJ (2014) Suspected impaired driving case involving alpha-pyrrolidinovalerophenone, methylone and ethylone. J Anal Toxicol 38:615–617
14. Hasegawa K, Suzuki O, Wurita A, Minakata K, Yamagishi I, Nozawa H, Gonmori K, Watanabe K (2014) Postmortem distribution of α-pyrrolidinovalerophenone and its metabolite in body fluids and solid tissues in a fatal poisoning case measured by LC–MS–MS with the standard addition method. Forensic Toxicol 32:225–234
15. Gil D, Adamowicz P, Skulska A, Tokarczyk B, Stanaszek R (2013) Analysis of 4-MEC in biological and non-biological material–three case reports. Forensic Sci Int 228:e11–e15
16. McIntyre IM, Hamm CE, Aldridge L, Nelson CL (2013) Acute methylone intoxication in an accidental drowning–a case report. Forensic Sci Int 231:e1–e3
17. Carbone PN, Carbone DL, Carstairs SD, Luzi SA (2013) Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol 34:26–28
18. Saito T, Namera A, Osawa M, Aoki H, Inokuchi S (2013) SPME–GC–MS analysis of α-pyrrolidinovaleorophenone in blood in a fatal poisoning case. Forensic Toxicol 31:328–332
19. Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug “bath salts” containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69–75
20. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188–191
21. Dickson AJ, Vorce SP, Levine B, Past MR (2010) Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34:162–168
22. Wikstrom M, Thelander G, Nystrom I, Kronstrand R (2010) Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J Anal Toxicol 34:594–598
23. Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202:e62–e63
24. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol 32:9–18
25. Roesner P (2014) Designer drugs online news: 4-methoxy-2-PVP. http://designer-drugs.de. Accessed 29 Dec 2014
26. US DEA (2013) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666
27. US DEA (2014) Schedules of controlled substances: temporary placement of 10 synthetic cathinones into schedule I. Final rule. Fed Regist 79:12938–12943
28. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562
29. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470
30. Kaizaki A, Tanaka S, Numazawa S (2014) New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J Toxicol Sci 39:1–6
31. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213
32. Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15
33. Dargan PI, Sedefov R, Gallegos A, Wood DM (2011) The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 3:454–463
34. Springer D, Peters FT, Fritschi G, Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B 773:25–33
35. Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 796:253–266
36. Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH (2003) Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 33:989–998
37. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952–964
38. Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233
39. Tyrkko E, Pelander A, Ketola RA, Ojanpera I (2013) In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal Bioanal Chem 405:6697–6709
40. Shima N, Katagi M, Kamata H, Matsuta S, Sasaki K, Kamata T, Nishioka H, Miki A, Tatsuno M, Zaitsu K, Ishii A, Sato T, Tsuchihashi H, Suzuki K (2014) Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol 32:59–67
41. Namera A, Konuma K, Kawamura M, Saito T, Nakamoto A, Yahata M, Ohta S, Miyazaki S, Shiraishi H, Nagao M (2014) Time-course profile of urinary excretion of intravenously administered α-pyrrolidinovalerophenone and α-pyrrolidinobutiophenone in a human. Forensic Toxicol 32:68–74
42. Uralets V, Rana S, Morgan S, Ross W (2014) Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. J Anal Toxicol 38:233–241
43. Zaitsu K, Katagi M, Tsuchihashi H, Ishii A (2014) Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism. Forensic Toxicol 32:1–8
44. Castaneto M, Wohlfarth A, Pang S, Zhu M, Scheidweiler K, Kronstrand R, Huestis M (2015) Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicol 33:295–310
45. Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA (2015) Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J. doi:10.1208/s12248-015-9721-0
46. Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472
47. McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M (2008) An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol 6:121–129
48. Friscia M, Wolf S, Mohr ALA, Diamond FX, Yeakel JK,Logan BK (2015) Identification of major metabolites in human blood and urine associated with the ingestion of alpha PVP. Paper presented at the American Academy of Forensic Sciences, Orlando, Florida, February 19, 2015
49. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152–155